Skip to main
STOK

STOK Stock Forecast & Price Target

STOK Analyst Ratings

Based on 9 analyst ratings
Strong Buy
Strong Buy 67%
Buy 22%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

Stoke Therapeutics Inc. is advancing its proprietary TANGO approach to restore protein expression, focusing on innovative treatments for diseases such as Dravet syndrome through its lead candidate, zorevunersen. Recent data from Phase I/II studies indicate significant seizure reductions of approximately 82% and cognitive improvements associated with zorevunersen, enhancing the company's risk profile as it prepares for potential Phase 3 trials. The firm's revenue projections for zorevunersen have been adjusted upwards, anticipating a FY28 launch and indicating promising financial upside should the FDA expedite its approval process.

Bears say

Stoke Therapeutics Inc faces potential challenges that contribute to a negative outlook on its stock, primarily stemming from concerns about patent protection and competitive pressures in the Dravet syndrome market. The possibility of a key patent not being issued, extended, or becoming disputed poses significant risks to the company's valuation and market success, which could lead to downward revisions. Additionally, the current treatment landscape for Dravet syndrome is competitive, with multiple therapies achieving substantial market shares, potentially hindering the adoption of Stoke's lead product, zorevunersen, even if it demonstrates long-term benefits.

STOK has been analyzed by 9 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 22% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Stoke Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Stoke Therapeutics Inc (STOK) Forecast

Analysts have given STOK a Strong Buy based on their latest research and market trends.

According to 9 analysts, STOK has a Strong Buy consensus rating as of Mar 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $36.22, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $36.22, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Stoke Therapeutics Inc (STOK)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.